Copperleaf Capital LLC Decreases Stock Holdings in IQVIA Holdings Inc. $IQV

Copperleaf Capital LLC reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,575 shares of the medical research company’s stock after selling 394 shares during the quarter. Copperleaf Capital LLC’s holdings in IQVIA were worth $721,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the company. Verdence Capital Advisors LLC acquired a new stake in IQVIA in the second quarter valued at $3,612,000. Patton Fund Management Inc. purchased a new stake in shares of IQVIA in the 2nd quarter worth about $231,000. Heritage Investors Management Corp grew its stake in IQVIA by 10.5% in the 2nd quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock valued at $16,500,000 after acquiring an additional 9,909 shares during the last quarter. Nordea Investment Management AB increased its holdings in IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after acquiring an additional 606,391 shares in the last quarter. Finally, Private Advisor Group LLC raised its position in IQVIA by 11.6% during the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after acquiring an additional 566 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $217.60 on Wednesday. The stock has a market capitalization of $37.06 billion, a price-to-earnings ratio of 29.85, a price-to-earnings-growth ratio of 2.43 and a beta of 1.34. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $228.12. The stock’s fifty day simple moving average is $203.84 and its 200-day simple moving average is $179.79.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. During the same period in the prior year, the firm posted $2.84 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on IQV. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. Mizuho raised their price target on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Cowen downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Monday, November 3rd. Baird R W raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. Finally, Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $240.61.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.